UroGen Pharma Raises $100M in Public Offering

TL;DR

UroGen just closed a $100M share offering, boosting their war chest.

AI Summary

UroGen Pharma Ltd. announced on June 17, 2024, the closing of its previously announced underwritten public offering of 10,350,000 ordinary shares, raising approximately $100 million in gross proceeds. The offering included the full exercise of the underwriters' option to purchase an additional 1,350,000 ordinary shares at the public offering price of $9.65 per share.

Why It Matters

This capital infusion provides UroGen Pharma with significant financial resources to advance its pipeline and operations, potentially accelerating drug development and market entry.

Risk Assessment

Risk Level: medium — While raising capital is positive, the success of the company still depends on the efficacy and market adoption of its drug candidates.

Key Numbers

• $100M — Gross Proceeds (Capital raised from the public offering)
• 10.35M — Shares Offered (Number of ordinary shares sold in the offering)
• $9.65 — Price Per Share (The price at which shares were sold)

Key Players & Entities

• UroGen Pharma Ltd. (company) — Registrant
• June 17, 2024 (date) — Closing date of the offering
• 10,350,000 (dollar_amount) — Number of ordinary shares offered
• $100 million (dollar_amount) — Gross proceeds from the offering
• 1,350,000 (dollar_amount) — Additional shares purchased under underwriters' option
• $9.65 (dollar_amount) — Public offering price per share

FAQ

Key Financial Figures

• $17.50 — price to the public in the offering was $17.50 per share (or $17.499 per pre-funded wa
• $17.499 — n the offering was $17.50 per share (or $17.499 per pre-funded warrant). The gross proc
• $107.5 m — fering are expected to be approximately $107.5 million, before deducting underwriting di
• $0.001 — warrant will have an exercise price of $0.001 per ordinary share, subject to customar

Filing Documents

• d854991d8k.htm (8-K) — 36KB
• d854991dex11.htm (EX-1.1) — 254KB
• d854991dex41.htm (EX-4.1) — 72KB
• d854991dex51.htm (EX-5.1) — 13KB
• d854991dex52.htm (EX-5.2) — 13KB
• d854991dex991.htm (EX-99.1) — 10KB
• d854991dex992.htm (EX-99.2) — 10KB
• g854991g0618050749230.jpg (GRAPHIC) — 2KB
• g854991g0618140349027.jpg (GRAPHIC) — 2KB
• 0001193125-24-163498.txt ( ) — 643KB
• urgn-20240617.xsd (EX-101.SCH) — 3KB
• urgn-20240617_lab.xml (EX-101.LAB) — 18KB
• urgn-20240617_pre.xml (EX-101.PRE) — 11KB
• d854991d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding, among other things, the Company's expectations about the timing and completion of the offering and expected gross proceeds from the offering. The words "expect," "may," "will," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to the Company's inability, or the inability of Underwriters, to satisfy the conditions to closing for the offering; uncertainties associated with the Company's ongoing and planned clinical trials; the Company's RTGel technology may not perform as expected; the Company may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology; the impacts of general macroeconomic and geopolitical conditions, high inflation, and uncertain credit and financial markets on the Company's business, clinical trials, and financial position; and other risks and uncertainties that are described in the Risk Factors section of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 13, 2024, and other filings the Company makes with the SEC from time to time. The events and circumstances discussed in such forward-looking statements may not occur, and the Company's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit Number Description 1.1 Underwriting Agreement, dated June 17, 2024, by and among the Company, TD Securities (USA) LLC and Guggenheim Securities, LLC. 4.1 Form of June 2024 Pre-Funded Warrant. 5.1 Opinion of Erdinast, Ben Nathan, Toledano & Co., Israeli counsel to the Registrant, as to the validity of the Registrant's Ordinary Shares. 5.2 Opinion of Cooley LLP. 23.1 Consent of Erdinast, Ben Nathan, Toledano & Co. (included in Exhibit 5.1). 23.2 Consent of Cooley LLP (included in Exhibit 5.2). 99.1 Press Release dated June 17, 2024. 99.2 Press Release dated June 17, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 18, 2024 UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer